Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797869 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
A Phase 2 study of Diabetes Mellitus, Type 2 and Diabetic Peripheral Neuropathy, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 20
- Study locations
NCT06797869: Active Phase 2 study of Diabetes Mellitus, Type 2 and Diabetic Peripheral Neuropathy, sponsored by Novo Nordisk A/S.
NCT06797869 is a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetic Peripheral Neuropathy that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 142 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06797869, a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetic Peripheral Neuropathy, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Primary Outcome
Measured as score on a scale.
Conditions Studied
Interventions
- DRUG CagriSema (Cagrilintide B and Semaglutide I)
- DRUG Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Study Locations (20)
Texas
- DM Clinical - CyFair - Houston
- Radiance Clinical Research - Lampasas
- DM Clinical - CyFair - San Antonio
- DM Clinical Research - San Antonio
Florida
- My Preferred Research - Miami
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
California
- eStudySite - La Mesa
- Linda Vista Health Care Ctr - San Diego
Illinois
- Foot & Ankle Center of Illinois - Springfield
Maryland
- Velocity Clinical Research Rockville - Rockville
Missouri
- Amicis Centers of Clinical Research - St Louis
New Mexico
- DM Clinical - CyFair - Albuquerque
New York
- Southgate Medical Group, LLP - West Seneca
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2026-08-21 |
| Phase | Phase 2 |
What the registry record for NCT06797869 still lists
NCT06797869 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which CagriSema (Cagrilintide B and Semaglutide I) is the first listed.
NCT06797869 names 20 study sites across 14 states, led by Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06797869 about?
NCT06797869 is a clinical study titled "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy". This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study ...
What is the current status of trial NCT06797869?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2025-01-29. Estimated completion is 2026-08-21.
What conditions does trial NCT06797869 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy.
What interventions are being tested in trial NCT06797869?
The interventions under investigation include: CagriSema (Cagrilintide B and Semaglutide I) (DRUG), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (DRUG).
Who is sponsoring clinical trial NCT06797869?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797869 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06797869's enrollment target sits among peer trials
142 181st of 348 higher than 168 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
-
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI